| scholarly article | Q13442814 |
| P50 | author | Sam S. Chang | Q91553580 |
| P2093 | author name string | Daniel A Barocas | |
| Todd M Morgan | |||
| Peter E Clark | |||
| S Duke Herrell | |||
| Opal Lin-Tsai | |||
| Joseph A Smith | |||
| Kelly L Stratton | |||
| Michael S Cookson | |||
| Samuel D Kaffenberger | |||
| P2860 | cites work | Statin drugs and risk of advanced prostate cancer | Q36688183 |
| The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer | Q36718982 | ||
| Emerging indications for statins: a pluripotent family of agents with several potential applications | Q37066246 | ||
| EAU guidelines on renal cell carcinoma: the 2010 update | Q37773064 | ||
| Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro | Q39820701 | ||
| Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma | Q39961148 | ||
| Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500,000 veterans. | Q44677443 | ||
| 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis | Q45205118 | ||
| Statin use and the risk of kidney cancer: a population-based case-control study | Q46134100 | ||
| Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients | Q46710487 | ||
| A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. | Q53398163 | ||
| The Risk of Cancer in Users of Statins | Q63865877 | ||
| ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma | Q84947425 | ||
| Cancer statistics, 2012 | Q27860574 | ||
| Statins and the risk of colorectal cancer | Q28176056 | ||
| The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators | Q29547887 | ||
| Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma | Q29618608 | ||
| Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram | Q33627815 | ||
| The genetic basis of kidney cancer: a metabolic disease | Q34087148 | ||
| The association between statin medication and progression after surgery for localized renal cell carcinoma | Q34206127 | ||
| Novel aspects of mevalonate pathway inhibitors as antitumor agents | Q34270512 | ||
| Statins and cancer risk: a meta-analysis | Q34481478 | ||
| HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis | Q34605246 | ||
| Statin use and reduced cancer-related mortality | Q34645107 | ||
| Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. | Q34899343 | ||
| The statins as anticancer agents | Q35049816 | ||
| Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts | Q35354232 | ||
| Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. | Q35383553 | ||
| Statin use and breast cancer: prospective results from the Women's Health Initiative. | Q36480676 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 21.e11-21.e17 | |
| P577 | publication date | 2014-10-31 | |
| P1433 | published in | Urologic Oncology | Q2113446 |
| P1476 | title | Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma | |
| P478 | volume | 33 |
| Q90060658 | Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation |
| Q38661937 | Components of metabolic syndrome and prognosis of renal cell cancer |
| Q49855458 | Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials |
| Q38881902 | Induction of cell cycle arrest, DNA damage, and apoptosis by nimbolide in human renal cell carcinoma cells |
| Q47333254 | Medication use and kidney cancer survival: A population-based study. |
| Q36600872 | Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities |
| Q35792565 | Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma |
| Q64889471 | Rising Serum Uric Acid Level Is Negatively Associated with Survival in Renal Cell Carcinoma. |
| Q41295014 | Statin Use and Serum Lipid Levels Are Associated With Survival Outcomes After Surgery for Renal Cell Carcinoma |
| Q54112866 | Targeting the mevalonate pathway suppresses VHL-deficient CC-RCC through a HIF-dependent mechanism. |
| Q38584232 | The Prognostic Effect of Statin Use on Urologic Cancers: An Updated Meta-Analysis of 35 Observational Studies. |
| Q33803789 | The value of complementing administrative data with abstracted information on smoking and obesity: A study in kidney cancer |
Search more.